RU2005137578A - OPTIMIZED FC OPTIONS AND METHODS FOR PRODUCING THEM - Google Patents

OPTIMIZED FC OPTIONS AND METHODS FOR PRODUCING THEM Download PDF

Info

Publication number
RU2005137578A
RU2005137578A RU2005137578/13A RU2005137578A RU2005137578A RU 2005137578 A RU2005137578 A RU 2005137578A RU 2005137578/13 A RU2005137578/13 A RU 2005137578/13A RU 2005137578 A RU2005137578 A RU 2005137578A RU 2005137578 A RU2005137578 A RU 2005137578A
Authority
RU
Russia
Prior art keywords
variant
affinity
polypeptide
antibody
group
Prior art date
Application number
RU2005137578/13A
Other languages
Russian (ru)
Other versions
RU2337107C2 (en
Inventor
Грегори Алан ЛАЗАР (US)
Грегори Алан ЛАЗАР
Артур Дж. ЧИРИНО (US)
Артур Дж. ЧИРИНО
Вэй ДАНГ (US)
Вэй ДАНГ
Джон Рудольф ДИСДЖАРЛЕЙС (US)
Джон Рудольф ДИСДЖАРЛЕЙС
Стивен Коль ДОБЕРСТЕЙН (US)
Стивен Коль ДОБЕРСТЕЙН
Роберт Дж. ХЭЙЕС (US)
Роберт Дж. ХЭЙЕС
Шер Бахадур КАРКИ (US)
Шер Бахадур КАРКИ
Омид ВАФА (US)
Омид Вафа
Original Assignee
Ксенкор, Инк. (Us)
Ксенкор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38312218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2005137578(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ксенкор, Инк. (Us), Ксенкор, Инк. filed Critical Ксенкор, Инк. (Us)
Publication of RU2005137578A publication Critical patent/RU2005137578A/en
Application granted granted Critical
Publication of RU2337107C2 publication Critical patent/RU2337107C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Claims (43)

1. Fc-вариант исходного полипептида Fc, который содержит, по меньшей мере, одну аминокислотную модификацию в Fc-участке указанного исходного полипептида Fc, причем указанная модификация имеет место в положении, выбранном из группы, состоящей из: 228, 230, 231, 232, 240, 244, 245, 247, 262, 263, 266, 271, 273, 275, 281, 284, 291, 299, 302, 304, 313, 323, 325, 328, 332, и 336, где белок указанного Fc-варианта демонстрирует измененное связывание с FcγR по сравнению с исходным полипептидом Fc, причем нумерация соответствует индексу EU.1. Fc-variant of the original Fc polypeptide, which contains at least one amino acid modification in the Fc region of the specified source Fc polypeptide, and this modification takes place at a position selected from the group consisting of: 228, 230, 231, 232 , 240, 244, 245, 247, 262, 263, 266, 271, 273, 275, 281, 284, 291, 299, 302, 304, 313, 323, 325, 328, 332, and 336, where the protein of said Fc the variant shows altered binding to FcγR compared to the original Fc polypeptide, and the numbering corresponds to the EU index. 2. Fc-вариант по п.1, который включает, по меньшей мере, одну замену в положении, выбранном из группы, состоящей из: 230, 240, 244, 245, 247, 262, 263, 266, 273, 275, 299, 302, 313, 323, 325, 328, и 332.2. The Fc variant according to claim 1, which includes at least one substitution in the position selected from the group consisting of: 230, 240, 244, 245, 247, 262, 263, 266, 273, 275, 299 , 302, 313, 323, 325, 328, and 332. 3. Fc-вариант по п.1, где указанное измененное связывание представляет собой увеличение аффинности указанного варианта Fc к указанному FcγR.3. The Fc variant of claim 1, wherein said altered binding is an increase in the affinity of said Fc variant for said FcγR. 4. Fc-вариант по п.3, который связывается с более высокой аффинностью с мышиным FcγR.4. The Fc variant according to claim 3, which binds with higher affinity to murine FcγR. 5. Fc-вариант по п.3, где указанный FcγR является Fc-рецептором человека, выбранным из группы, состоящей из FcγRI, FcγRIIa, FcγRIIb, FcγRIIc и FcγRIIIa.5. The Fc variant of claim 3, wherein said FcγR is a human Fc receptor selected from the group consisting of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc and FcγRIIIa. 6. Fc-вариант по п.3, который связывается с большей аффинностью с FcγRI и FcγRIIIa человека, но демонстрирует неизмененную аффинность к рецепторам человека, выбранным из группы, состоящей из FcγRIIa, FcγRIIb и FcγRIIc.6. The Fc variant according to claim 3, which binds with greater affinity to human FcγRI and FcγRIIIa, but exhibits unchanged affinity for human receptors selected from the group consisting of FcγRIIa, FcγRIIb and FcγRIIc. 7. Fc-вариант по п.6, который демонстрирует неизмененную аффинность к FcγRIIa, FcγRIIb и FcγRIIc.7. The Fc variant according to claim 6, which demonstrates an unchanged affinity for FcγRIIa, FcγRIIb and FcγRIIc. 8. Fc-вариант по п.3, где увеличение аффинности связывания с одним или несколькими рецепторами FcγRII человека больше, чем увеличение аффинности связывания с FcγRI или FcγRIIIa человека.8. The Fc variant of claim 3, wherein the increase in binding affinity for one or more human FcγRII receptors is greater than the increase in binding affinity for human FcγRI or FcγRIIIa. 9. Fc-вариант по п.3, где увеличение аффинности связывания с FcγRIIa, FcγRIIb и FcγRIIc одинаковое.9. The Fc variant of claim 3, wherein the increase in binding affinity for FcγRIIa, FcγRIIb, and FcγRIIc is the same. 10. Fc-вариант по п.3, где увеличение аффинности связывания с FcγRIIc больше, чем увеличение аффинности связывания с FcγRIIb.10. The Fc variant of claim 3, wherein the increase in binding affinity for FcγRIIc is greater than the increase in binding affinity for FcγRIIb. 11. Fc-вариант по п.3, который связывается с большей аффинностью с FcγRIIa человека, но демонстрирует неизмененную аффинность к рецепторам человека, выбранным из группы, состоящей из FcγRI, FcγRIIb, FcγRIIc и FcγRIIIa.11. The Fc variant according to claim 3, which binds with greater affinity to human FcγRIIa, but exhibits unchanged affinity for human receptors selected from the group consisting of FcγRI, FcγRIIb, FcγRIIc and FcγRIIIa. 12. Fc-вариант по п.11, который демонстрирует неизмененную аффинность к FcγRI, FcγRIIb, FcγRIIc и FcγRIIIa.12. The Fc variant according to claim 11, which shows unchanged affinity for FcγRI, FcγRIIb, FcγRIIc and FcγRIIIa. 13. Fc-вариант по любому из пп.1-12, который связывается с большей аффинностью с FcRn.13. The Fc variant according to any one of claims 1-12, which binds with greater affinity to FcRn. 14. Fc-вариант по любому из пп.1-12, который связывается с неизмененной аффинностью с FcRn.14. The Fc variant according to any one of claims 1 to 12, which binds to unchanged affinity with FcRn. 15. Fc-вариант по любому из пп.1-12, который связывается со сниженной аффинностью с FcRn.15. The Fc variant according to any one of claims 1 to 12, which binds with reduced affinity to FcRn. 16. Fc-вариант по любому из пп.1-12, который связывается с большей аффинностью с C1q или увеличивает зависимую от комплемента цитотоксичность (CDC).16. The Fc variant according to any one of claims 1-12, which binds with greater affinity to C1q or increases complement dependent cytotoxicity (CDC). 17. Fc-вариант по любому из пп.1-12, который связывается с неизмененной аффинностью с C1q или увеличивает зависимую от комплемента цитотоксичность (CDC).17. The Fc variant according to any one of claims 1-12, which binds to unchanged affinity with C1q or increases complement dependent cytotoxicity (CDC). 18. Fc-вариант по п.1, который дополнительно включает сконструированную гликоформу.18. The Fc variant according to claim 1, which further includes engineered glycoform. 19. Fc-вариант по п.18, где указанная сконструированная гликоформа включает измененный уровень фукозилирования или разветвленных олигосахаридов по сравнению с исходным полипептидом Fc.19. The Fc variant of claim 18, wherein said engineered glycoform comprises an altered level of fucosylation or branched oligosaccharides as compared to the starting Fc polypeptide. 20. Fc-вариант по п.18, в котором указанная сконструированная гликоформа улучшает эффекторную функцию.20. The Fc variant of claim 18, wherein said engineered glycoform improves effector function. 21. Fc-вариант по п.1, который модулирует эффекторную функцию по сравнению с исходным полипептидом Fc.21. The Fc variant according to claim 1, which modulates effector function compared to the original Fc polypeptide. 22. Fc-вариант по п.21, где указанная эффекторная функция представляет собой зависимую от антител опосредованную клетками цитотоксичность (ADCC).22. The Fc variant of claim 21, wherein said effector function is antibody dependent cell mediated cytotoxicity (ADCC). 23. Fc-вариант по п.22, который улучшает ADCC в присутствии эффекторных клеток человека по сравнению с указанным исходным полипептидом Fc.23. The Fc variant of claim 22, which improves ADCC in the presence of human effector cells compared to said parent Fc polypeptide. 24. Fc-вариант по п.22, где указанное улучшение ADCC является увеличением активности, таким, что ЕС50 указанного варианта Fc приблизительно в 5 раз больше, чем ЕС50 для исходного полипептида Fc.24. The Fc variant of claim 22, wherein said improvement in ADCC is an increase in activity such that the EC50 of said Fc variant is about 5 times greater than the EC50 for the parent Fc polypeptide. 25. Fc-вариант по п.23, где указанное улучшение ADCC является увеличением активности, таким, что ЕС50 указанного варианта Fc приблизительно в от 5 раз до 1000 раз больше ЕС50 для исходного полипептида Fc.25. The Fc variant of claim 23, wherein said improvement in ADCC is an increase in activity such that the EC50 of said Fc variant is about 5 times to 1000 times greater than the EC50 for the parent Fc polypeptide. 26. Fc-вариант по п.23, где указанное улучшение ADCC является увеличением эффективности таким, что максимальная ADCC приблизительно в 2 раза выше, чем ADCC для исходного полипептида Fc.26. The Fc variant of claim 23, wherein said improvement in ADCC is an increase in efficiency such that the maximum ADCC is about 2 times higher than the ADCC for the parent Fc polypeptide. 27. Fc-вариант по п.26, который улучшает ADCC в присутствии мышиных эффекторных клеток по сравнению с указанным исходным полипептидом Fc дикого типа.27. The Fc variant of claim 26, which improves ADCC in the presence of murine effector cells compared to said wild-type starting Fc polypeptide. 28. Fc-вариант по п.21, где указанная эффекторная функция представляет собой зависимый от антител опосредованный клетками фагоцитоз (ADCP).28. The Fc variant of claim 21, wherein said effector function is antibody dependent cell mediated phagocytosis (ADCP). 29. Fc-вариант по п.28, который улучшает ADCP по сравнению с указанным исходным полипептидом Fc.29. The Fc variant of claim 28, which improves ADCP compared to said parent Fc polypeptide. 30. Fc-вариант по п.25 или 29, где зависимая от комплемента цитотоксичность (CDC) не меняется.30. The Fc variant of claim 25 or 29, wherein complement-dependent cytotoxicity (CDC) does not change. 31. Fc-вариант по п.25 или 29, где CDC отсутствует.31. The Fc variant of claim 25 or 29, wherein the CDC is absent. 32. Fc-вариант по п.1, где указанный полипептид обладает специфичностью к антигену-мишени, выбранному из группы, состоящей из CD4, CD19, CD20, CD22, CD25, CD30, CD33, CD52, CD80, В7-1, В7-2, CLTA-4, BAFF-R, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNF-α и VEGF.32. The Fc variant of claim 1, wherein said polypeptide has specificity for a target antigen selected from the group consisting of CD4, CD19, CD20, CD22, CD25, CD30, CD33, CD52, CD80, B7-1, B7- 2, CLTA-4, BAFF-R, Her2 / neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNF-α and VEGF. 33. Fc-вариант по п.1, включающий модификацию, выбранную из группы, состоящей из: 228Е, 228К, 228Y, 228G, 230Е, 230Y, 230G, 231Е, 231К, 231Y, 231Р, 231G, 232Е, 232К, 232Y, 232G, 262Е, 262F, 271D, 271Е, 271N, 271Q, 271K, 271R, 271S, 271Т, 271Н, 271А, 271V, 271L, 271I, 271F, 271М, 271Y, 271W, 271G, 275L, 281D, 281K, 281Y, 281Р, 284Е, 284N, 284Т, 284L, 284Y, 291D, 291Е, 291Q, 291Т, 291Н, 291I, 291G, 299D, 299Е, 299N, 299Q, 299K, 299R, 299L, 299F, 299М, 299Y, 299W, 299Р, 299G, 304D, 304N, 304Т, 304Н, 304L, 325K, 325R, 325S, 325F, 325М, 325Y, 325W, 325Р, 325G, 328D, 328Q, 328K, 328R, 328S, 328Т, 328V, 328I, 328Y, 328W, 328P, 328G, 332K, 332R, 332S, 332V, 332L, 332F, 332M, 332W, 332P, 332G, 336E, 336K, 336Y, 230А, 240А, 240I, 240М, 240Т, 244Н, 245А, 247G, 247V, 262A, 262Е, 2621, 262T, 263A, 263I, 263M, 263T, 266A, 266I, 266M, 266T, 2731, 275W, 299A, 299Е, 299F, 299H, 299I, 299L, 299S, 299V, 302I, 313F, 323I, 325A, 325D, 325E, 325H, 325I, 325L, 325Q, 325T, 325V, 328A, 328D, 328E, 328F, 328H, 328I, 328M, 328N, 328Q, 328Т, 328V, 332A, 332D, 332E, 332H, 332N, 332Q, 332T, и 332Y.33. The Fc variant according to claim 1, comprising a modification selected from the group consisting of: 228E, 228K, 228Y, 228G, 230E, 230Y, 230G, 231E, 231K, 231Y, 231P, 231G, 232E, 232K, 232Y, 232G, 262E, 262F, 271D, 271E, 271N, 271Q, 271K, 271R, 271S, 271T, 271H, 271A, 271V, 271L, 271I, 271F, 271M, 271Y, 271W, 271G, 275L, 281D, 281K, 281Y, 281P, 284E, 284N, 284T, 284L, 284Y, 291D, 291E, 291Q, 291T, 291H, 291I, 291G, 299D, 299E, 299N, 299Q, 299K, 299R, 299L, 299F, 299M, 299Y, 299W, 299W, 299W, 299W, 299W 299G, 304D, 304N, 304T, 304H, 304L, 325K, 325R, 325S, 325F, 325M, 325Y, 325W, 325P, 325G, 328D, 328Q, 328K, 328R, 328S, 328T, 328V, 328I, 328Y, 328W, 328P, 328G, 332K, 332R, 332S, 332V, 332L, 332F, 332M, 332W, 332P, 332G, 336E, 336K, 336Y, 230A, 240A, 240I, 240M, 240T, 244H, 245A, 247G, 247V, 262A, 262E, 2621, 262T, 263A, 263I, 263M, 263T, 266A, 266I, 266M, 266T, 2731, 275W, 299A, 299E, 299F, 299H, 299I, 299L, 299S, 299V, 302I, 3 13F, 323I, 325A, 325D, 325E, 325H, 325I, 325L, 325Q, 325T, 325V, 328A, 328D, 328E, 328F, 328H, 328I, 328M, 328N, 328Q, 328T, 328V, 332A, 332D, 332E, 332H, 332N, 332Q, 332T, and 332Y. 34. Fc-вариант по п.1, где указанный исходный полипептид Fc является антителом, включающим указанный вариант Fc.34. The Fc variant of claim 1, wherein said parent Fc polypeptide is an antibody comprising said Fc variant. 35. Fc-вариант по п.1, который представляет собой слитый с Fc белок, включающий указанный вариант Fc.35. The Fc variant of claim 1, which is an Fc fusion protein comprising said Fc variant. 36. Фармацевтическая композиция, содержащая Fc-вариант по п.1 и фармацевтически приемлемый носитель.36. A pharmaceutical composition comprising an Fc variant of claim 1 and a pharmaceutically acceptable carrier. 37. Способ лечения млекопитающего, нуждающегося в указанном лечении, включающий введение Fc-варианта по п.1.37. A method of treating a mammal in need of said treatment, comprising administering an Fc variant of claim 1. 38. Fc-вариант по п.1 или 33, содержащий, по меньшей мере, одну модификацию, выбранную из группы, состоящей из: A330L/I332E, D265F/N297E/I332E, D265Y/N297D/I332E, D265Y/N297D/T299L/I332E, F241E/F243Q/V262T/V264E, F241E/F243Q/V262T/V264E/I332E, F241E/F243R/V262E/V264R, F241E/F243R/V262E/V264R/I332E, F241E/F243Y/V262T/V264R, F241E/F243Y/V262T/V264R/I332E, F241L/F243L/V262I/V264I, F241L/V262I, F241R/F243Q/V262T/V264R, F241R/F243Q/V262T/V264R/I332E, F241W/F243W/V262A/V264A, F241Y/F243Y/V262T/V264T, F241Y/F243Y/V262T/V264T/N297D/I332E, F243L/V262I/V264W, F243L/V264I, L328D/I332E, L328E/I332E, L328H/I332E, L328I/I332E, L328M/I332E, L328N/I332E, L328Q/I332E, L328T/I332E, L328V/I332E, N297D/A330Y/I332E, N297D/I332E, N297D/I332E/S239D/A330L, N297D/S298A/A330Y/I332E, N297D/T299E/I332E, N297D/T299F/I332E, N297D/T299H/I332E, N297D/T299I/I332E, N297D/T299L/I332E, N297D/T299V/I332E, N297E/I332E, N297S/I332E, P230A/E233D/I332E, P244H/P245A/P247V, S239D/A330L/I332E, S239D/A330Y/I332E, S239D/A330Y/I332E/K326E, S239D/A330Y/I332E/K326T, S239D/A330Y/I332E/L234I, S239D/A330Y/I332E/L235D, S239D/A330Y/I332E/V240I, S239D/A330Y/I332E/V264T, S239D/A330Y/I332E/V266I, S239D/D265F/N297D/I332E, S239D/D265H/N297D/I332E, S239D/D265I/N297D/I332E, S239D/D265L/N297D/I332E, S239D/D265T/N297D/I332E, S239D/D265V/N297D/I332E, S239D/D265Y/N297D/I332E, S239D/I332D, S239D/I332E, S239D/I332E/A330I, S239D/I332N, S239D/I332Q, S239D/N297D/I332E, S239D/N297D/I332E/A330Y, S239D/N297D/I332E/A330Y/F241S/F243H/V262T/V264T, S239D/N297D/I332E/K326E, S239D/N297D/I332E/L235D, S239D/S298A/I332E, S239D/V264I/A330L/I332E, S239D/V264I/I332E, S239D/V264I/S298A/I332E, S239E/D265N, S239E/D265Q, S239E/I332D, S239E/I332E, S239E/I332N, S239E/I332Q, S239E/N297D/I332E, S239E/V264I/A330Y/I332E, S239E/V264I/I332E, S239E/V264I/S298A/A330Y/I332E, S239N/A330L/I332E, S239N/A330Y/I332E, S239N/I332D, S239N/I332E, S239N/I332N, S239N/I332Q, S239N/S298A/I332E, S239Q/I332D, S239Q/I332E, S239Q/I332N, S239Q/I332Q, S239Q/V264I/I332E, S298A/I332E, V264E/N297D/I332E, V264I/A330L/I332E, V264I/A330Y/I332E,V264VI332E, V264I/S298A/I332E, Y296D/N297D/I332E, Y296E/N297D/I332E, Y296H/N297D/I332E, Y296N/N297D/I332E, Y296Q/N297D/I332E, и Y296T/N297D/I332E.38. The Fc variant according to claim 1 or 33, containing at least one modification selected from the group consisting of: A330L / I332E, D265F / N297E / I332E, D265Y / N297D / I332E, D265Y / N297D / T299L / I332E; F241E / F243Q / V262T / V264E; F241E / F243Q / V262T / V264E / I332E; F241E / F243R / V262E / V264R; F241E / F243R / V262E / V264R / I332E V262T / V264R / I332E, F241L / F243L / V262I / V264I, F241L / V262I, F241R / F243Q / V262T / V264R, F241R / F243Q / V262T / V264R / I332E, F241W22624 V26426 / F241W2 V2 F2 V264T, F241Y / F243Y / V262T / V264T / N297D / I332E, F243L / V262I / V264W, F243L / V264I, L328D / I332E, L328E / I332E, L328H / I332E, L328I / I323 / 321/321/323/321/32 I332E, L328T / I332E, L328V / I332E, N297D / A330Y / I332E, N297D / I332E, N297D / I332E / S239D / A330L, N297D / S298A / A330Y / I332E, N297D / T29922932932932922922932932922932932932929292929 T299H / I332E, N297D / T299I / I332E, N297D / T299L / I332E, N297D / T299V / I332E, N297E / I332E, N297S / I332E, P230A / E233D / I 332E, P244H / P245A / P247V, S239D / A330L / I332E, S239D / A330Y / I332E, S239D / A330Y / I332E / K326E, S239D / A330Y / I332E / K326T, S239D / A330Y / I332E / 2323D / A330Y / I332E L235D; S239D / A330Y / I332E / V240I; S239D / A330Y / I332E / V264T; S239D / A330Y / I332E / V266I; S239D / D265F / N297D / I332E; S239D / D265L / N297D / I332E; S239D / D265T / N297D / I332E; S239D / D265V / N297D / I332E; S239D / D265Y / N297D / I332E; S239D / I332D S239D / I332Q; S239D / N297D / I332E; S239D / N297D / I332E / A330Y; S239D / N297D / I332E / A330Y / F241S / F243H / V262T / V264T; S239D / S298A / I332E, S239D / V264I / A330L / I332E, S239D / V264I / I332E, S239D / V264I / S298A / I332E, S239E / D265N, S239E / D265Q, S239E / I3E32, 2323E23E23E23E23E23E23E23E23E23E23323323323323 I332Q, S239E / N297D / I332E, S239E / V264I / A330Y / I332E, S239E / V264I / I332E, S239E / V264I / S298A / A330Y / I332E, S239N / A330L / I332E, S239N / I303 / I332E, S239N / I332E / SY23NN I332E, S239N / I332N, S239N / I332Q, S239N / S298A / I332E, S239 Q / I332D, S239Q / I332E, S239Q / I332N, S239Q / I332Q, S239Q / V264I / I332E, S298A / I332E, V264E / N297D / I332E, V264I / A330L / I332E, V2642 / I332E / V364I232I3VE I332E, Y296D / N297D / I332E, Y296E / N297D / I332E, Y296H / N297D / I332E, Y296N / N297D / I332E, Y296Q / N297D / I332E, and Y296T / N297D / I332E. 39. Fc-вариант по п.1 или 33, дополнительно содержащий модификацию, выбранную из группы, состоящей из: 227Е, 227К, 227Y, 227G, 233N, 233Q, 233К, 233R, 233S, 233Т, 233Н, 233А, 233V, 233L, 233I, 233F, 233М, 233Y, 233W, 233G, 234К, 234R, 234S, 234А, 234М, 234W, 234Р, 234G, 235Е, 235К, 235R, 235А, 235М, 235W, 235Р, 235G, 236D, 236Е, 236N, 236Q, 236К, 236R, 236S, 236Т, 236Н, 236А, 236V, 236L, 236I, 236F, 236M, 236Y, 236W, 236P, 237D, 237E, 237N, 237Q, 237K, 237R, 237S, 237T, 237H, 237V, 237L, 237I, 237F, 237M, 237Y, 237W, 237P, 238D, 238E, 238N, 238Q, 238K, 238R, 238S, 238T, 238H, 238V, 238L, 238I, 238F, 238M, 238Y, 238W, 238G, 239Q, 239K, 239R, 239V, 239L, 239I, 239M, 239W, 239P, 239G, 241D, 241E, 241Y, 243E, 246D, 246E, 246H, 246Y, 249Q, 249H, 249Y, 255E, 255Y, 258S, 258H, 258Y, 260D, 260E, 260H, 260Y, 264D, 264E, 264N, 264Q, 264K, 264R, 264S, 264H, 264W, 264P, 264G, 265Q, 265K, 265R, 265S, 265T, 265H, 265V, 265L, 265I, 265F, 265M, 265Y, 265W, 265P, 267E, 267Q, 267K, 267R, 267V, 267L, 267I, 267F, 267M, 267Y, 267W, 267P, 268D, 268E, 268Q, 268K, 268R, 268T, 268V, 268L, 268I, 268F, 268M, 268W, 268P, 268G, 269K, 269S, 269V, 269I, 269M, 269W, 269P, 269G, 270R, 270S, 270L, 270I, 270F, 270M, 270Y, 270W, 270P, 270G, 272D, 272R, 272T, 272H, 272V, 272L, 272F, 272M, 272W, 272P, 272G, 274D, 274N, 274S, 274H, 274V, 274I, 274F, 274M, 274W, 274P, 274G, 276D, 276T, 276H, 276V, 276I, 276F, 276M, 276W, 276P, 276G, 278D, 278N, 278Q, 278R, 278S, 278H, 278V, 278L, 278I, 278M, 278P, 278G, 280K, 280L, 280W, 280P, 280G, 282E, 282K, 282Y, 282P, 282G, 283K, 283H, 283L, 283Y, 283P, 283G, 285D, 285E, 285Q, 285K, 285Y, 285W, 286E, 286Y, 286P, 286G, 288D, 288E, 288Y, 290D, 290N, 290H, 290L, 290W, 292D, 292E, 292T, 292Y, 293N, 293R, 293S, 293T, 293H, 293V, 293L, 293I, 293F, 293M, 293Y, 293W, 293P, 293G, 294K, 294R, 294S, 294T, 294H, 294V, 294L, 294I, 294F, 294M, 294Y, 294W, 294P, 294G, 295D, 295E, 295N, 295R, 295S, 295T, 295H, 295V, 295I, 295F, 295M, 295Y, 295W, 295P, 295G, 296K, 296R, 296A, 296V, 296M, 296G, 297Q, 297K, 297R, 297T, 297H, 297V, 297L, 297I, 297F, 297M, 297Y, 297W, 297P, 297G, 298D, 298E, 298Q, 298K, 298R, 298I, 298F, 298M, 298Y, 298W, 300D, 300E, 300N, 300Q, 300K, 300R, 300S, 300Т, 300Н, 300А, 300V, 300М, 300W, 300Р, 300G, 301D, 301Е, 301Н, 301Y, 303D, 303Е, 303Y, 305Е, 305Т, 305Y, 317Е, 317Q, 318Q, 318Н, 318L, 318Y, 320N, 320S, 320Н, 320V, 320L, 320F, 320Y, 320W, 320Р, 320G, 322D, 322S, 322V, 322I, 322F, 322Y, 322W, 322Р, 322G, 324Н, 324F, 324М, 324W, 324Р, 324G, 326Р, 327Е, 327К, 327R, 327Н, 327V, 3271, 327F, 327М, 327Y, 327W, 327Р, 329D, 329Е, 329N, 329Q, 329К, 329R, 329S, 329Т, 329Н, 329V, 329L, 329I, 329M, 329Y, 329W, 329G, 330E, 330N, 330Т, 330Р, 330G, 331D, 331Q, 331R, 331Т, 331L, 331I, 331F, 331М, 331Y, 331W, 333L, 333F, 333М, 333Р, 334Р, 335N, 335S, 335Н, 335V, 335L, 335I, 335F, 335M, 335W, 335P, 335G, 337E, 337N, 337H, 233D, 234D, 234E, 234F, 234H, 234I, 234N, 234Q, 234T, 234V, 234Y, 235D, 235F, 235H, 235I, 235N, 235Q, 235S, 235T, 235V, 235Y, 239D, 239E, 239F, 239H, 239N, 239Q, 239T, 239Y, 241E, 241L, 241R, 241S, 241W, 241Y, 243H, 243L, 243Q, 243R, 243W, 243Y, 264A, 264E, 264F, 264I, 264L, 264M, 264R, 264T, 264W, 264Y, 265F, 265G, 265Н, 265I, 265L, 265N, 265Q, 265Т, 265V, 265Y, 267D, 267H, 267L, 267N, 267Q, 267T, 269F, 269H, 269L, 269N, 269R, 269T, 269Y, 270H, 270Q, 270T, 272I, 272K, 272S, 272Y, 274E, 274L, 274R, 274T, 274Y, 276E, 276L, 276R, 276S, 276Y, 278E, 278K, 278T, 278W, 283R, 296D, 296E, 296H, 296I, 296L, 296N, 296Q, 296S, 296T, 297D, 297E, 297S, 298A, 298H, 298N, 298T, 318R, 320D, 320I, 320T, 322H, 322T, 324D, 324I, 324L, 324R, 324T, 324V, 324Y, 326E, 326I, 326L, 326T, 327D, 327L, 327N, 327S, 327T, 329F, 330F, 330H, 330I, 330L, 330M, 330R, 330S, 330V, 330W, 330Y, 331H, 331V, 333A, 333H, 333I, 333T, 333Y, 334A, 334F, 334I, 334T, 335D, 335R, и 335Y.39. The Fc variant according to claim 1 or 33, further comprising a modification selected from the group consisting of: 227E, 227K, 227Y, 227G, 233N, 233Q, 233K, 233R, 233S, 233T, 233H, 233A, 233V, 233L 233I, 233F, 233M, 233Y, 233W, 233G, 234K, 234R, 234S, 234A, 234M, 234W, 234P, 234G, 235E, 235K, 235R, 235A, 235M, 235W, 235P, 235G, 236D, 236E, 236E, 236E, 236E, 236E , 236Q, 236K, 236R, 236S, 236T, 236H, 236A, 236V, 236L, 236I, 236F, 236M, 236Y, 236W, 236P, 237D, 237E, 237N, 237Q, 237K, 237R, 237S, 237T, 237H, , 237L, 237I, 237F, 237M, 237Y, 237W, 237P, 238D, 238E, 238N, 238Q, 238K, 238R, 238S, 238T, 238H, 238V, 238L, 238I, 238F, 238M, 238Y, 238W, 238G, , 239K, 239R, 239V, 239L, 239I, 239M, 239W, 239P, 239G, 241D, 241E, 241Y, 243E, 246D, 246E, 246H, 246Y, 249Q, 249H, 249Y, 255E, 255Y, 258S, 258H, 258H, , 260D, 260E, 260H, 260Y, 264D, 264E, 264N, 264Q, 264K, 264R, 264S, 264H, 264W, 264P, 264G, 265Q, 265K, 265R, 265S, 265 T, 265H, 265V, 265L, 265I, 265F, 265M, 265Y, 265W, 265P, 267E, 267Q, 267K, 267R, 267V, 267L, 267I, 267F, 267M, 267Y, 267W, 267P, 268D, 268E, 268Q, 268K, 268R, 268T, 268V, 268L, 268I, 268F, 268M, 268W, 268P, 268G, 269K, 269S, 269V, 269I, 269M, 269W, 269P, 269G, 270R, 270S, 270L, 270I, 270F, 270M, 270Y, 270W, 270P, 270G, 272D, 272R, 272T, 272H, 272V, 272L, 272F, 272M, 272W, 272P, 272G, 274D, 274N, 274S, 274H, 274V, 274I, 274F, 274M, 274W, 274P, 274G, 276D, 276T, 276H, 276V, 276I, 276F, 276M, 276W, 276P, 276G, 278D, 278N, 278Q, 278R, 278S, 278H, 278V, 278L, 278I, 278M, 278P, 278G, 280K, 280L, 280L 280W, 280P, 280G, 282E, 282K, 282Y, 282P, 282G, 283K, 283H, 283L, 283Y, 283P, 283G, 285D, 285E, 285Q, 285K, 285Y, 285W, 286E, 286Y, 286P, 286G, 288D, 288E, 288Y, 290D, 290N, 290H, 290L, 290W, 292D, 292E, 292T, 292Y, 293N, 293R, 293S, 293T, 293H, 293V, 293L, 293I, 293F, 293M, 293Y, 293W, 293P, 293 294K, 294R, 294S, 294T, 294H, 294V, 294L, 294I, 294F, 294M, 294Y, 294W, 294P, 294G, 295D, 295E, 295N, 2 95R, 295S, 295T, 295H, 295V, 295I, 295F, 295M, 295Y, 295W, 295P, 295G, 296K, 296R, 296A, 296V, 296M, 296G, 297Q, 297K, 297R, 297T, 297H, 297V, 297L, 297V, 297V 297I, 297F, 297M, 297Y, 297W, 297P, 297G, 298D, 298E, 298Q, 298K, 298R, 298I, 298F, 298M, 298Y, 298W, 300D, 300E, 300N, 300Q, 300K, 300R, 300S, 300T, 300H, 300A, 300V, 300M, 300W, 300P, 300G, 301D, 301E, 301H, 301Y, 303D, 303E, 303Y, 305E, 305T, 305Y, 317E, 317Q, 318Q, 318H, 318L, 318Y, 320N, 320S, 320Н, 320V, 320L, 320F, 320Y, 320W, 320Р, 320G, 322D, 322S, 322V, 322I, 322F, 322Y, 322W, 322Р, 322G, 324Н, 324F, 324М, 324W, 324Р, 324G, 326Р, 327Е, 327K, 327R, 327H, 327V, 3271, 327F, 327M, 327Y, 327W, 327P, 329D, 329E, 329N, 329Q, 329K, 329R, 329S, 329T, 329H, 329V, 329L, 329I, 329M, 329Y, 329W, 329G, 330E, 330N, 330T, 330P, 330G, 331D, 331Q, 331R, 331T, 331L, 331I, 331F, 331M, 331Y, 331W, 333L, 333F, 333M, 333P, 334P, 335N, 335S, 335H, 335V, 335L, 335I, 335F, 335M, 335W, 335P, 335G, 337E, 337N, 337H, 233D, 234D, 234E, 234F, 234H, 234I, 234N, 234Q, 234T, 234V, 234Y, 235D, 235F, 235H, 235I, 235N, 235Q, 235S, 235T, 235V, 235Y, 239D, 239E, 239F, 239H, 239H, 239Q, 239T, 239Y, 241E, 241L, 241R, 241S, 241W, 241Y, 243H, 243L, 243Q, 243R, 243W, 243Y, 264A, 264E, 264F, 264I, 264L, 264M, 264R, 264T, 264W, 264W, 264W 265F, 265G, 265H, 265I, 265L, 265N, 265Q, 265T, 265V, 265Y, 267D, 267H, 267L, 267N, 267Q, 267T, 269F, 269H, 269L, 269N, 269R, 269T, 269Y, 270H, 270Q 270T, 272I, 272K, 272S, 272Y, 274E, 274L, 274R, 274T, 274Y, 276E, 276L, 276R, 276S, 276Y, 278E, 278K, 278T, 278W, 283R, 296D, 296E, 296H, 296I, 296I, 296 296N, 296Q, 296S, 296T, 297D, 297E, 297S, 298A, 298H, 298N, 298T, 318R, 320D, 320I, 320T, 322H, 322T, 324D, 324I, 324L, 324R, 324T, 324V, 324Y, 326E, 326I, 326L, 326T, 327D, 327L, 327N, 327S, 327T, 329F, 330F, 330H, 330I, 330L, 330M, 330R, 330S, 330V, 330W, 330Y, 331H, 331V, 333A, 333H, 333I, 333T, 333Y, 334A, 334F, 334I, 334T, 335D, 335R, and 335Y. 40. Fc-вариант по п.1, который дополнительно содержит набор модификаций, выбранных из 241W/243W, 267Q/327S, 243L/264I, 234I/235D, 264E/297D/332E, 239E/265N, 239E/265Q, 239E/265G, 267L/327S и 240I/266I.40. The Fc variant according to claim 1, which further comprises a set of modifications selected from 241W / 243W, 267Q / 327S, 243L / 264I, 234I / 235D, 264E / 297D / 332E, 239E / 265N, 239E / 265Q, 239E / 265G, 267L / 327S and 240I / 266I. 41. Fc-вариант по п.33, где указанное антитело является полноразмерным антителом.41. The Fc variant of claim 33, wherein said antibody is a full length antibody. 42. Fc-вариант по п.33, где указанное антитело является человеческим антителом.42. The Fc variant of claim 33, wherein said antibody is a human antibody. 43. Fc-вариант по п.33, где указанное антитело является фрагментом антитела.43. The Fc variant of claim 33, wherein said antibody is a fragment of an antibody.
RU2005137578/13A 2003-05-02 2004-03-26 OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION RU2337107C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46760603P 2003-05-02 2003-05-02
US60/467,606 2003-05-02
US47783903P 2003-06-12 2003-06-12
US60/477,839 2003-06-12
US10/672,280 2003-09-26

Publications (2)

Publication Number Publication Date
RU2005137578A true RU2005137578A (en) 2007-06-10
RU2337107C2 RU2337107C2 (en) 2008-10-27

Family

ID=38312218

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005137578/13A RU2337107C2 (en) 2003-05-02 2004-03-26 OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION

Country Status (5)

Country Link
JP (1) JP5226613B2 (en)
KR (1) KR100973564B1 (en)
CA (1) CA2766627C (en)
IL (1) IL213648A (en)
RU (1) RU2337107C2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
RU2714153C2 (en) * 2014-06-12 2020-02-12 Ф. Хоффманн-Ля Рош Аг METHOD OF SELECTING ANTIBODIES WITH MODIFIED INTERACTION WITH FcRn
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2799595C (en) 2010-05-27 2022-08-16 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
TWI812066B (en) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 Antibody having calcium-dependent antigen-binding ability
AU2012222252B2 (en) 2011-02-25 2016-08-25 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc antibody
TWI687439B (en) 2011-06-30 2020-03-11 中外製藥股份有限公司 Heterodimerized polypeptide
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
KR20210074395A (en) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 Drug containing carrier into cell for forming immune complex
CA2872195A1 (en) * 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
TW202237660A (en) * 2012-08-24 2022-10-01 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
JP6433297B2 (en) 2012-12-27 2018-12-05 中外製薬株式会社 Heterodimerized polypeptide
MX368005B (en) 2013-03-15 2019-09-13 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use.
EP4039281A1 (en) * 2013-03-15 2022-08-10 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage
WO2014145000A2 (en) * 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
PT3708583T (en) * 2013-08-01 2022-05-13 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
KR102650420B1 (en) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN106872713A (en) * 2016-12-27 2017-06-20 许洋 A kind of immunomic mass spectrometry kit and preparation method of trace protein in situ detection
KR20200099807A (en) * 2019-02-15 2020-08-25 아주대학교산학협력단 Antibody Fragment With Constant Region of Antibody and Uses Thereof
CN112397159B (en) * 2019-08-19 2024-03-22 金色熊猫有限公司 Automatic entry method and device for clinical test report, electronic equipment and storage medium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1763097B (en) * 1999-01-15 2011-04-13 杰南技术公司 Polypeptide variants with altered effector function
EP2364996B1 (en) * 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
RU2714153C2 (en) * 2014-06-12 2020-02-12 Ф. Хоффманн-Ля Рош Аг METHOD OF SELECTING ANTIBODIES WITH MODIFIED INTERACTION WITH FcRn
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases

Also Published As

Publication number Publication date
IL213648A0 (en) 2011-07-31
KR20090059170A (en) 2009-06-10
IL213648A (en) 2017-01-31
KR100973564B1 (en) 2010-08-03
CA2766627A1 (en) 2004-11-18
RU2337107C2 (en) 2008-10-27
CA2766627C (en) 2019-12-03
JP5226613B2 (en) 2013-07-03
JP2009209150A (en) 2009-09-17

Similar Documents

Publication Publication Date Title
RU2005137578A (en) OPTIMIZED FC OPTIONS AND METHODS FOR PRODUCING THEM
IL265538A (en) Optimized fc variants and uses thereof
JP2009209150A5 (en)
US20200031929A1 (en) Therapeutic use of anti-cs1 antibodies
ES2589912T3 (en) Specific antibodies for the BCR complex and procedures for their use
WO2008091954A4 (en) Optimized cd40 antibodies and methods of using the same
EP2301576B1 (en) Therapeutic use of Anti-CS1 Antibodies
US20070224189A1 (en) CD20 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
US20070003546A1 (en) Optimized Fc variants and methods for their generation
US20110206701A1 (en) Use of anti-cs1 antibodies for treatment of rare lymphomas
CA2903546A1 (en) Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
US20210061908A1 (en) Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
WO2024068777A1 (en) Modified ace2 proteins with improved activity against sars-cov-2
AU2015213401B9 (en) Therapeutic use of anti-CS1 antibodies
AU2008229860B2 (en) Optimized Fc variants and methods for their generation
AU2012216291B2 (en) Therapeutic use of anti-CS1 antibodies